IS8113A - Notkun á IBAT-tálma til að meðhöndla eða fyrirbyggja hægðatregðu - Google Patents

Notkun á IBAT-tálma til að meðhöndla eða fyrirbyggja hægðatregðu

Info

Publication number
IS8113A
IS8113A IS8113A IS8113A IS8113A IS 8113 A IS8113 A IS 8113A IS 8113 A IS8113 A IS 8113A IS 8113 A IS8113 A IS 8113A IS 8113 A IS8113 A IS 8113A
Authority
IS
Iceland
Prior art keywords
treat
prevent constipation
ibat inhibitors
ibat
inhibitors
Prior art date
Application number
IS8113A
Other languages
English (en)
Inventor
Roland Abrahamsson Hasse
Gillberg Per-Goran
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9956272&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS8113(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS8113A publication Critical patent/IS8113A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
IS8113A 2003-04-05 2005-11-01 Notkun á IBAT-tálma til að meðhöndla eða fyrirbyggja hægðatregðu IS8113A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0307918.3A GB0307918D0 (en) 2003-04-05 2003-04-05 Therapeutic use
PCT/GB2004/001396 WO2004089350A1 (en) 2003-04-05 2004-04-01 Use of an ibat inhibitor for the treatment of prophylaxis of constipation

Publications (1)

Publication Number Publication Date
IS8113A true IS8113A (is) 2005-11-01

Family

ID=9956272

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8113A IS8113A (is) 2003-04-05 2005-11-01 Notkun á IBAT-tálma til að meðhöndla eða fyrirbyggja hægðatregðu

Country Status (33)

Country Link
US (1) US7514421B2 (is)
EP (2) EP1894564B1 (is)
JP (2) JP4870552B2 (is)
KR (1) KR101321577B1 (is)
CN (1) CN100366241C (is)
AR (1) AR043985A1 (is)
AT (2) ATE513550T1 (is)
AU (1) AU2004228731B2 (is)
BR (1) BRPI0408858A (is)
CA (1) CA2520109C (is)
CO (1) CO5640076A2 (is)
CY (2) CY1107424T1 (is)
DE (1) DE602004012079T2 (is)
DK (2) DK1610770T3 (is)
ES (2) ES2299832T3 (is)
GB (1) GB0307918D0 (is)
HK (1) HK1085666A1 (is)
IL (1) IL170913A (is)
IS (1) IS8113A (is)
MX (1) MXPA05010706A (is)
MY (1) MY137757A (is)
NO (1) NO335140B1 (is)
NZ (1) NZ542835A (is)
PL (2) PL1894564T3 (is)
PT (2) PT1894564E (is)
RU (2) RU2342928C2 (is)
SA (1) SA04250066B1 (is)
SI (2) SI1610770T1 (is)
TW (1) TWI338577B (is)
UA (1) UA84141C2 (is)
UY (1) UY28258A1 (is)
WO (1) WO2004089350A1 (is)
ZA (1) ZA200507996B (is)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
CN1582151A (zh) 2001-09-08 2005-02-16 阿斯特拉曾尼卡有限公司 用于治疗高脂血症、具有回肠胆汁酸转运(ibat)抑制活性的苯并硫氮杂䓬和苯并硫杂二氮杂䓬衍生物
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0304194D0 (en) * 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) * 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
AR057828A1 (es) * 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
RU2480453C2 (ru) 2007-03-08 2013-04-27 Альбирео Аб Новые соединения
WO2010062861A2 (en) 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
EP2575821B1 (en) * 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
SI2637668T1 (sl) 2010-11-08 2016-11-30 Albiero Ab IBAT inhibitorji za zdravljenje jetrnih bolezni
CN107375932B (zh) 2011-10-28 2021-12-21 夏尔人类遗传性治疗公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
EA029581B1 (ru) 2011-10-28 2018-04-30 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Применение ингибиторов рециркуляции желчных кислот для лечения холестатического заболевания печени или прурита
CA2907230A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
EP2968262A1 (en) 2013-03-15 2016-01-20 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
KR101420315B1 (ko) * 2014-03-19 2014-07-17 남봉길 약학적 액제 조성물
US20170143738A1 (en) 2014-06-25 2017-05-25 Ea Pharma Co., Ltd. Solid formulation and method for stabilizing the same
KR20220082931A (ko) 2014-06-25 2022-06-17 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
EP3337513A1 (en) 2015-08-17 2018-06-27 Ferring B.V. Liquid formulations containing picosulfate and magnesium citrate
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US11236099B2 (en) 2017-06-20 2022-02-01 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
US10428109B1 (en) 2018-03-09 2019-10-01 Elobix Ab Process for the preparation of 1,5-benzothiazepine compounds
BR112020017353A2 (pt) 2018-03-09 2020-12-15 Elobix Ab Processos para a preparação de um composto e de uma modificação de cristal iv de elobixibat.
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202015699A (zh) 2018-06-05 2020-05-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
WO2019245449A1 (en) 2018-06-20 2019-12-26 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
MX2021009622A (es) 2019-02-12 2021-11-04 Mirum Pharmaceuticals Inc Metodos para tratar la colestasis.
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158276A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
CR20220315A (es) 2019-12-04 2022-10-26 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar
JP2023504644A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
JP2023537285A (ja) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
KR20230106651A (ko) 2020-11-12 2023-07-13 알비레오 에이비 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트
EP4255565A1 (en) 2020-12-04 2023-10-11 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022166680A1 (zh) * 2021-06-25 2022-08-11 苏州科睿思制药有限公司 奥德昔巴特的晶型及其制备方法和用途
US20230338392A1 (en) 2022-04-22 2023-10-26 Albireo Ab Subcutaneous administration of an asbt inhibitor

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8705837A1 (es) 1985-01-10 1987-05-16 Tanabe Seiyaku Co Un procedimiento para la preparacion de derivados de naftaleno.
JPS6310746A (ja) 1986-07-01 1988-01-18 Tanabe Seiyaku Co Ltd ナフタレン誘導体
US4900757A (en) 1988-12-08 1990-02-13 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane
DE3930696A1 (de) 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5250524A (en) 1990-12-06 1993-10-05 Hoechst Aktiengesellschaft Bile acid derivatives, process for their preparation and use of these compounds as pharmaceuticals
KR100252428B1 (ko) 1991-10-17 2000-04-15 시오노 요시히코 리그난유사체,이의제조방법및이를함유한항지혈증제
ES2087422T3 (es) 1991-12-20 1996-07-16 Hoechst Ag Polimeros y oligomeros de derivados de acidos biliares, procedimiento para su preparacion y su empleo como medicamento.
JPH05186357A (ja) * 1991-12-31 1993-07-27 Shigeo Ochi 飲食物消化分解産物吸収抑制手段
GEP20001968B (en) * 1992-01-21 2000-03-05 Glaxo Spa Arilthio Compounds as Antibacterial and Antiviral Agents
GB9203347D0 (en) 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
DE59307759D1 (de) 1992-06-12 1998-01-15 Hoechst Ag Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
JP3411036B2 (ja) 1993-04-16 2003-05-26 塩野義製薬株式会社 リグナン系化合物の製造方法
EP0624593A3 (de) 1993-05-08 1995-06-07 Hoechst Ag Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
TW289020B (is) 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
TW289021B (is) 1993-05-08 1996-10-21 Hoechst Ag
ZA956647B (en) 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
US5994391A (en) 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
WO1996008484A1 (en) 1994-09-13 1996-03-21 Monsanto Company Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GB9423172D0 (en) 1994-11-17 1995-01-04 Wellcom Foundation The Limited Hypolipidemic benzothiazepines
CN1515567A (zh) 1996-03-11 2004-07-28 G.D.ɪ����˾ 具有作为回肠胆汁酸转运和牛磺胆酸盐吸收抑制剂活性的新的苯并噻庚因
EP0929575A4 (en) 1996-08-23 2004-09-08 Human Genome Sciences Inc NEW HUMAN GROWTH FACTORS.
JPH1072371A (ja) 1996-08-28 1998-03-17 Sankyo Co Ltd 回腸型胆汁酸トランスポーター阻害剤
GB9704208D0 (en) 1997-02-28 1997-04-16 Glaxo Group Ltd Chemical compounds
HUP0002395A3 (en) 1997-03-11 2002-12-28 G D Searle & Co Chicago Combined pharmaceutical compositions containing ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors
ES2198613T3 (es) 1997-03-14 2004-02-01 Aventis Pharma Deutschland Gmbh 1,4-benzotiazepina-1,1-dioxidos hipolipidemicos.
DK0869121T3 (da) 1997-04-04 2004-09-20 Aventis Pharma Gmbh Hypolipidæmiske propanolaminderivater
DE19845402B4 (de) 1998-10-02 2005-04-07 Aventis Pharma Deutschland Gmbh Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO1998056757A1 (fr) 1997-06-11 1998-12-17 Sankyo Company, Limited Derives de benzylamine
AUPO763197A0 (en) * 1997-06-30 1997-07-24 Sigma Pharmaceuticals Pty Ltd Health supplement
DK1042314T3 (da) 1997-12-19 2003-07-14 Searle & Co Fremgangsmåde til fremstilling af enantiomert berigede tetrahydrobenzothiepinoxider
GB9800428D0 (en) 1998-01-10 1998-03-04 Glaxo Group Ltd Chemical compounds
DE19825804C2 (de) 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
DE19845406C2 (de) 1998-10-02 2001-10-18 Aventis Pharma Gmbh Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19845403B4 (de) 1998-10-02 2005-02-10 Aventis Pharma Deutschland Gmbh Mit Gallensäuren verknüpfte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2000035889A1 (fr) 1998-12-11 2000-06-22 Sankyo Company, Limited Benzylamines substituees
DK1140190T3 (da) 1998-12-23 2002-12-23 Searle Llc Kombinationer af ileumgaldesyretransport-inhibitorer og galdesyre-sekvestreringsmidler til cardiovaskulære indikatorer
IL143944A0 (en) 1998-12-23 2002-04-21 Searle Llc Combinations for cardiovascular indications
NZ512537A (en) 1998-12-23 2003-11-28 G Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
PL348581A1 (en) 1998-12-23 2002-06-03 Searle Llc Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications
BR9916486A (pt) 1998-12-23 2002-02-05 Searle Llc Combinações de inibidores do transporte de ácidos biliares no ìleo e inibidores da proteìna de transferência do ester colesteril para indicações cardiovasculares
KR20020000139A (ko) 1999-02-12 2002-01-04 추후제출 회장 담즙산 수송 및 타우로콜산염 흡수의 억제제로서의활성을 보유하는 신규한 1,2-벤조티아제핀
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
SE9901387D0 (sv) 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
US6287609B1 (en) * 1999-06-09 2001-09-11 Wisconsin Alumni Research Foundation Unfermented gel fraction from psyllium seed husks
CZ290178B6 (cs) 1999-07-22 2002-06-12 Sankyo Company Limited Deriváty cyklobutenu
AU1302301A (en) 1999-11-08 2001-06-06 Sankyo Company Limited Nitrogenous heterocycle derivatives
CA2400021A1 (en) 2000-02-18 2001-08-23 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
WO2001068637A2 (en) 2000-03-10 2001-09-20 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
WO2001068096A2 (en) 2000-03-10 2001-09-20 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US20020183307A1 (en) 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
SE0003766D0 (sv) 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) * 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
WO2002053548A1 (en) 2000-12-27 2002-07-11 Banyu Pharmaceutical Co.,Ltd. Benzothiazepine derivatives
US6506921B1 (en) * 2001-06-29 2003-01-14 Virginia Tech Intellectual Properties, Inc. Amine compounds and curable compositions derived therefrom
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
CN1582151A (zh) * 2001-09-08 2005-02-16 阿斯特拉曾尼卡有限公司 用于治疗高脂血症、具有回肠胆汁酸转运(ibat)抑制活性的苯并硫氮杂䓬和苯并硫杂二氮杂䓬衍生物
GB0201850D0 (en) * 2002-01-26 2002-03-13 Astrazeneca Ab Therapeutic treatment
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0216321D0 (en) 2002-07-13 2002-08-21 Astrazeneca Ab Therapeutic treatment
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) * 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use

Also Published As

Publication number Publication date
SA04250066B1 (ar) 2008-09-22
CO5640076A2 (es) 2006-05-31
US20060199797A1 (en) 2006-09-07
ATE387194T1 (de) 2008-03-15
US7514421B2 (en) 2009-04-07
AU2004228731B2 (en) 2008-02-28
ATE513550T1 (de) 2011-07-15
DK1610770T3 (da) 2008-05-13
PT1610770E (pt) 2008-04-10
DE602004012079T2 (de) 2009-02-26
KR101321577B1 (ko) 2013-10-25
DK1894564T3 (da) 2011-08-29
PL1610770T3 (pl) 2008-07-31
NO20054369D0 (no) 2005-09-21
RU2342928C2 (ru) 2009-01-10
ZA200507996B (en) 2007-04-25
MXPA05010706A (es) 2005-12-12
CA2520109A1 (en) 2004-10-21
SI1894564T1 (sl) 2011-08-31
UA84141C2 (ru) 2008-09-25
CA2520109C (en) 2012-03-20
CY1111995T1 (el) 2015-11-04
ES2299832T3 (es) 2008-06-01
NO20054369L (no) 2005-11-15
GB0307918D0 (en) 2003-05-14
AR043985A1 (es) 2005-08-17
RU2008129204A (ru) 2010-01-27
MY137757A (en) 2009-03-31
EP1894564B1 (en) 2011-06-22
TW200505434A (en) 2005-02-16
JP2006522082A (ja) 2006-09-28
PL1894564T3 (pl) 2011-11-30
RU2005128792A (ru) 2006-05-10
BRPI0408858A (pt) 2006-04-11
CY1107424T1 (el) 2012-12-19
EP1610770B1 (en) 2008-02-27
EP1894564A2 (en) 2008-03-05
RU2482850C2 (ru) 2013-05-27
UY28258A1 (es) 2004-11-30
PT1894564E (pt) 2011-07-26
EP1610770A1 (en) 2006-01-04
JP4870552B2 (ja) 2012-02-08
EP1894564A3 (en) 2009-09-09
IL170913A (en) 2010-11-30
AU2004228731A1 (en) 2004-10-21
DE602004012079D1 (de) 2008-04-10
TWI338577B (en) 2011-03-11
NZ542835A (en) 2009-01-31
NO335140B1 (no) 2014-09-29
CN100366241C (zh) 2008-02-06
JP5421326B2 (ja) 2014-02-19
JP2011173925A (ja) 2011-09-08
HK1085666A1 (en) 2006-09-01
SI1610770T1 (sl) 2008-06-30
KR20050121241A (ko) 2005-12-26
WO2004089350A1 (en) 2004-10-21
ES2368350T3 (es) 2011-11-16
CN1771027A (zh) 2006-05-10

Similar Documents

Publication Publication Date Title
IS8113A (is) Notkun á IBAT-tálma til að meðhöndla eða fyrirbyggja hægðatregðu
LTC1761540I2 (lt) Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės-delta inhibitoriai
CY2013042I1 (el) Αναστολεις πυριδυλιου της σηματοδοτησης hedgehog
DK1485127T3 (da) Anvendelse af midler til behandling af inflammation
IS8913A (is) Afleiður 4-tetrazólýl-4-fenýlpiperidíns til þess að meðhöndla verk
IL212985A0 (en) Therapeutic uses of inhibitors of rtp801
IS8371A (is) Notkun breyttra sýklósporína til að meðhöndla HCVsjúkdóma
IL181524A0 (en) Heterocyclic compounds and methods of use
HRP20041029A2 (en) Therapeutic use of selcetive pde10 inhibitors
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
ZA200701660B (en) Isoindoline compounds and methods of their use
IS8511A (is) Píperasín gagnleg til meðferðar á verkjum
IS8359A (is) Vefjaverndandi frumuboðar til meðferðar og forvarnar á blóðeitrun og samloðunarmyndun
JP2006502186A5 (ja) β-グルカンの使用
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
IS7970A (is) PDE4-hemlar til að meðhöndla eitlafrumuæxli
NO20070042L (no) Behandling av hydrokarboner
DE602004004262D1 (de) Ultraschallbehandlung von gewebematrices
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
IS7963A (is) Efnasambönd með hamlandi virkni gegn prólýlólígópeptíðasa
DE602004011946D1 (de) Alkalisalze von protonenpumpen-hemmern
DE60317661D1 (de) Annelierte pyrrol-verbindungen als protonenpumpenhemmer zur behandlung von geschwüren
DE602007003350D1 (de) Behandlung von polysilazan-abfall
IS8496A (is) Samsetningar til meðhöndlunar á fjölgunarsjúkdómum
DE60308390D1 (de) Behandlung von Hyperurikämie